Personalized diabetes care: study tests if some patients can safely ditch mealtime insulin
NCT ID NCT06148376
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a personalized medicine approach in 239 people with type 2 diabetes who use multiple daily insulin injections. Researchers used blood tests (C-peptide and GAD antibodies) to see if some patients could safely stop their mealtime insulin and switch to other diabetes treatments. Participants wore a continuous glucose monitor and were followed for 6 months to check blood sugar control, safety, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
discontinuation of prandial insulin and switch to other diabetes treatments if indicated
What this could lead to
If successful, this could help doctors personalize diabetes care by safely reducing insulin injections for some patients, simplifying their treatment.
What could go wrong
This is an observational study, not a controlled trial, so results may not be definitive. The approach may only work for a subset of patients and requires careful monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centres Atenció Primària Lleida, Alt Pirineu i Aran
Lleida, Spain
-
Hospital Universitari Arnau de Vilanova
Lleida, 25198, Spain